by Alicia Gailliez, Business Development Manager, One Nucleus
Securing funding is always a top challenge for biotech companies. This blog will discuss how the uncertainty in the biotech funding landscape may be transforming into more positive tones as we see Nasdaq IPOs happening and private investment rounds returning. Amid this optimistic news, we celebrate some case studies of investment raised by One Nucleus members, highlighting some of the ways that One Nucleus helps to support our members to scale their innovation and businesses, often in a challenging environment.
The global…
So you think buying cyber insurance means your business will avoid a major nightmare?
You’ve bought a cyber insurance policy to help protect your company against devastating cyber-attacks. It looks comprehensive so you can finally sleep at night. But before you get too carried away, is that really the case? Many companies which have been victims of a cyber-attack held cyber insurance policies. That cyber insurance did not prevent them from being the next victim. Of course, you will be glad you had the policy if the worst does happen, but it is essential to understand the difference between…
Report from the Genesis Fringe Event held on 6 December 2023 by Tony Jones
For the past decade, a number of satellite sessions have been held across London and online as part of the build up to the annual Genesis Conference which has been a key fixture in the life science calendar for over twenty years. With sessions that vary in size, content, topic focus and exclusivity, the Genesis Fringe, which is described further in the Genesis Review/One Nucleus at BIO-Europe Spring 2023 publication launched in March, forms an informal London Life Science Week. The Fringe affords participants access to…
By Tony Jones, CEO, One Nucleus
On the evening of 21 March 2024 at No. 11 Cavendish Square in London, for the first time in its history, One Nucleus delivered an Annual Awards Dinner to recognise and celebrate the breadth and depth of excellence within the One Nucleus network.
One Nucleus sees itself as a very inclusive not-for-profit membership organisation for life science companies, seeking to support all connected organisations on their journey to success irrespective of size, business model, stage of development, or geography. It is One Nucleus’s firm belief that a successful…
By Alicia Gailliez, Business Development Manager, One Nucleus
The ON Helix session ‘New Horizons in Biomarker Technologies’ will look at the innovations that have the potential for earlier diagnosis and precision treatment across a wide range of diseases. The results of a recent study offering potential for early detection of Alzheimer’s’ disease offered a good exemplification of the possible. Researchers found that looking for a specific protein in blood called p-tau217 to be highly accurate in detecting the disease. These results could have a significant impact on screening for…
When it comes to recruitment, the life sciences industry is undoubtedly highly competitive. With demand for skilled professionals often outpacing the supply, attracting (and retaining) qualified candidates with the right expertise can be a significant challenge for many life science companies.
From nurturing a positive work culture to empowering and developing your people for success, Pioneer Group sets out some top tips for building a high-performance team as a life science company.
Invest in Graduate Programmes
Investing in graduate outreach can help to bridge the skills gap in…
A Strategic Guide for Life Science Companies
In the ever-evolving landscape of the life sciences industry, companies are constantly seeking new avenues for growth and expansion. This video presents a compelling opportunity for life science organizations to look beyond the traditional powerhouses of Boston, New York, and Los Angeles and explore the untapped potential within the diverse US market. Featuring insights from industry veterans like Tony Jones of One Nucleus – the Life Sciences & Healthcare membership organisation headquartered in Cambridge – and Chris Howie of GTM…
Guest blog post by David Fleming, Chief Technology Officer at Mitigo
AI is a hot topic. Many life science and biomedical businesses are already using AI or exploring its potential to revolutionise the way they deliver their services. But it’s not all good news. Cybercriminals are also interested in the benefits of AI and how it can make their activities more profitable. Here, we discuss the potential impact of AI from a cybercrime perspective, and provide some tips on how to mitigate the risk AI presents.
Here are three aspects to consider.
Local unauthorised use of AI tools.
Staff members…
It’s cybersecurity awareness month and our cybersecurity partner Mitigo are sharing helpful advice and guidance. This week they are helping practices with a strategy to defend against ransomware attacks. This guide highlights the five layers of defence that you should have lined up against this threat to keep your business secure.
View Ransomware guide
Guest blog post by RSM
ESG specialist, Steven Radcliffe, explains why it’s good for early-stage businesses to set up good governance processes and the impact of TCFD (Task Force on Climate Related Financial Disclosures) for more mature healthcare and life sciences businesses.Demonstrating strong ESG credentials in life sciences and healthcare businesses is no longer simply a 'nice-to-have', but business-critical. Younger generations, forming an increasing proportion of workforces, customer bases and clinical trial cohorts, are typically highly attuned to ESG matters and want to align…